WEIGH THE IMPORTANCE OF YOUR ARV DECISION
Lighten the HIV Treatment Burden Today
Choose SYMTUZA® for sustained tolerability,* proven efficacy, and a protective resistance barrier1,2
Patient factors to consider when making your ARV choice
[XX]% OF PATIENTS HAVE COVERAGE FOR SYMTUZA® IN [CBSA]†‡
†This percentage may not represent 100% of formulary lives due to data limitations.
Collected in 04/22 and may change.
This information does not give advice or promise coverage or payment. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, restrictions, or requirements that may apply.
References: 1. Orkin C, Eron JJ, Rockstroh J, et al; AMBER Study Group. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34(5):707-718. 2. Eron JJ, Orkin C, Cunningham D, et al; EMERALD Study Group. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res. 2019;170:104543. 3. Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of mm/yy.